News

Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Benzinga.com1d
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
“We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration ... recently completing the REDEFINE 2 trial for CagriSema, which demonstrated 15.7% weight loss ...
Novo Nordisk cuts guidance as weight-loss drug market competition grows
Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth ...
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...
Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...